Clinical Trials Directory

Le20: Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : Epratuzumab
  • drug : Rituximab

Phase: N/A


Ages Eligible For Study:

18 Years - N/A

External Links

Stanford Medicine Resources:

Footer Links: